

REFERENCES

1. Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. *JAMA Neurol* 2017;74:216-24. <https://doi.org/10.1001/jamaneurol.2016.4467>
2. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. *Mov Disord* 2014;29:229-37. <https://doi.org/10.1002/mds.25751>
3. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. *Mov Disord* 2014;29:1273-80. <https://doi.org/10.1002/mds.25961>
4. Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. *Eur J Neurol* 2013;20:271-80. <https://doi.org/10.1111/j.1468-1331.2012.03840.x>

The Transparency Score is explained in [New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27.](#)

At the time the comment was prepared, information about this drug was available on the websites of the [Food and Drug Administration in the USA](#), and the [European Medicines Agency and the Therapeutic Goods Administration.](#)

A:

ANSWERS TO SELF-TEST QUESTIONS

1 True 2 False

Correction

The hot patient: acute drug-induced hyperthermia [Correction]

Aust Prescr 2019;42:79

<https://doi.org/10.18773/austprescr.2019.022>

First published 18 February 2019

A formatting error in the article by Nazila Jamshidi and Andrew Dawson has been corrected.

[View corrected article.](#)

The diaphoresis row in Table 3 (Clinical features of neuroleptic malignant syndrome, serotonin toxicity, anticholinergic syndrome and sympathomimetic syndrome) was incorrect. Diaphoresis in serotonin toxicity is moderate (not severe), it is not a feature of anticholinergic toxicity (not moderate), and it is moderate (not severe) in sympathomimetic syndrome.

EDITORIAL OFFICE

For general correspondence such as Letters to the Editor, contact the Editor.

Postal The Editor
 Australian Prescriber
 Level 5, 15 Moore Street
 Canberra, ACT 2600

Telephone +61 2 8217 8700

Email info@australianprescriber.com

Website nps.org.au/australian-prescriber

Twitter @AustPrescriber

SUBSCRIPTIONS

Australian Prescriber is published every two months online. All content is accessible free of charge in full text at nps.org.au/australian-prescriber. New drugs are published between issues as they become available.

An email alert can be sent to you when *Australian Prescriber* publishes new material. Subscribe or update your details at nps.org.au/australian-prescriber

For back issues, and copies of the Anaphylaxis wallchart and Switching-antidepressants poster, email info@australianprescriber.com

© 2019 NPS MedicineWise
 ABN 61 082 034 393

NPS MedicineWise Disclaimer

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information.